Does Zepbound Cause Headaches? What the Trial Tables Show Once You Read the Placebo Column

Almost every page answering this question quotes a percentage for the tirzepatide group and stops there. A percentage on its own cannot tell you whether a drug causes something, because plenty of people get headaches in any given six months whether or not they are taking anything. The number that answers the question is the difference between the two arms, and it is printed right next to the first one in the same table. Here it is.

Headache next to the placebo group, in one trial table

Read down the difference column and the table sorts itself into two groups. Nausea, diarrhea, vomiting and injection site reactions sit ten to twenty-six points above placebo. Those are the drug. Headache, at 1.9 points, sits with upper respiratory infections and back pain, and not far from COVID-19 and influenza, which both came out lower in the tirzepatide arm.

Nobody thinks tirzepatide prevents influenza. The influenza row is in the table because, over 72 weeks, things happen to people, and trials record all of it. Headache is much closer to that end of the table than to the nausea end. That is the honest answer to the question in the title, and it is the part that almost every article on this topic leaves out.

One caution about reading it too hard in the other direction: a 1.9 point difference in a trial of 579 people is small and this analysis was not designed to test it, so the table cannot rule out a real but modest effect. What it can tell you is the size of the effect you would be looking for, and it is not large.

Why headache is missing from the Zepbound label

It is a common observation on this topic that the label "does not list headache," usually offered without explanation. The explanation is a stated rule, and it is printed directly above the table.

Table 1 of the ZEPBOUND prescribing information is introduced with this sentence: the reactions shown "occurred more commonly with ZEPBOUND than with placebo and occurred in at least 2% of patients treated with ZEPBOUND." Two conditions, both of which must hold. Headache did not clear that bar in the pooled Study 1 and Study 2 population, so it is not in the table. Its absence is a statement about the size of the gap, not a claim that nobody gets headaches.

You can see the same rule produce the opposite result on another GLP-1 label. Wegovy uses an identical inclusion rule, "greater than or equal to 2% and greater than placebo," and headache clears it: 14% on Wegovy 2.4 mg against 10% on placebo, across 2,116 treated patients and 1,261 on placebo. Headache is listed for Wegovy and also appears in its "most common adverse reactions" summary. Same rule, two drugs, two different outcomes, which is a more useful comparison than either label on its own.

The one place headache does appear in the Zepbound label

Search the full prescribing information, Medication Guide and Instructions for Use for the word "headache" and it appears exactly once. Not in the adverse reactions section. It is in the Medication Guide, inside the list of the signs and symptoms of low blood sugar, alongside dizziness, sweating, confusion or drowsiness, blurred vision, slurred speech, shakiness, fast heartbeat and mood changes.

That single placement is arguably the most practical fact on this page. The label's position, read literally, is that the headache worth paying attention to on this drug is the one arriving with that company. A headache on its own is not flagged anywhere. A headache with sweating, shakiness and confusion is, and the label notes the risk of hypoglycemia is higher for people also taking insulin or a sulfonylurea.

Does the dose change it?

The most cited source for this is a 2023 meta-analysis of ten tirzepatide trials covering 6,836 participants. Its headache figures do rise across the three doses, and they are widely quoted for that reason. The confidence intervals are quoted much less often, and they change the picture.

The 10 mg interval runs from 1.10 to 11.96 and the 15 mg interval runs from 4.84 to 18.54. They overlap across most of their range, the participant numbers behind each row are in the low hundreds, and the authors report a P value of .429 for the difference across doses. By the conventional threshold that is not a significant trend. Several pages ranking for this query cite this paper and describe headaches as more common at higher doses without mentioning any of that. The figures are real; the trend they appear to show is not established by them.

The mechanisms that are actually plausible

If the drug itself contributes little directly, the headaches people genuinely experience still need an explanation. The label supports two indirect routes, and both are consequences of things Zepbound definitely does.

• Low blood sugar. This is the route the label itself connects to headache. In Study 2, among patients with type 2 diabetes, plasma glucose below 54 mg/dL was reported in 4.2% of Zepbound treated patients against 1.3% on placebo. In Study 1, without type 2 diabetes, it was 0.3% against none on placebo. The risk is meaningfully different between those two groups.
• Dehydration, by way of the gastrointestinal effects. The label is explicit that gastrointestinal reactions can lead to volume depletion, warning under acute kidney injury that the majority of reported events "occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea." Those reactions are common: 56% at every dose against 30% on placebo. If you are nauseated, drinking less and eating less, the headache has an obvious source that is not the molecule acting on your head.

Both of these point the same way. The thing to manage is usually the intake, not the headache.

A timing test you can run on yourself

Weekly dosing gives you something daily medications do not: a clean, repeating signal. If you record when headaches fall relative to your injection day, the pattern narrows the explanation considerably. Four to six weeks is enough.

1. Record your injection day and dose each week, and note every headache by date, not by memory at the end of the month.
2. Note alongside each one whether you ate normally and drank normally in the preceding day, and whether nausea was present.
3. Mark the weeks where your dose stepped up.
4. After four to six doses, read the shape:

• Clustered in the day or two after each injection, then clear: a pattern locked to dosing, worth showing your prescriber alongside the intake notes.
• Appearing after each dose increase and settling within a week or two: consistent with the escalation pattern the label describes for the gastrointestinal reactions, which it says mostly occurred during dose escalation and decreased over time.
• Tracking the days you ate or drank least, regardless of injection day: the intake route, which is the most actionable of the three.
• Evenly spread with no relationship to dose day, dose changes or intake: the pattern that looks like the placebo column. Worth investigating as its own thing rather than attributing to the drug.

This only works with a record kept as you go. That is the plain case for logging doses and symptoms in one place rather than reconstructing them in a waiting room. In Jabby, a side effect is logged against the dose it followed, so the "day two after the shot" pattern is visible without you having to remember anything. An app is not required to do this, a notebook works, but something has to hold four weeks of dates.

When a headache needs a doctor rather than a glass of water

The general rules for headaches apply here and are not specific to Zepbound, which is precisely why they matter: a serious headache does not become less serious because you happen to be on a GLP-1.

• A headache that arrives suddenly and severely, reaching its peak within seconds or a couple of minutes. That needs emergency assessment regardless of medication.
• A headache with sweating, shakiness, confusion, drowsiness, blurred vision or slurred speech. This is the combination the Zepbound Medication Guide lists under low blood sugar, and the label notes higher risk with insulin or a sulfonylurea.
• A headache with fever and a stiff neck, with new weakness or numbness, or with a change in vision or speech.
• Headaches that keep worsening week over week rather than settling, or that follow persistent vomiting or diarrhea, given the label's warning about dehydration and kidney injury.
• Any headache severe enough that you are considering skipping or changing a dose. That decision is your prescriber's.

Frequently asked questions

Are headaches a common side effect of Zepbound?

Headache is not listed as an adverse reaction in the Zepbound label, because it did not reach the label's threshold of at least 2% of patients and more often than placebo. In SURMOUNT-3 it was reported by 9.4% of the tirzepatide group, but also by 7.5% of the placebo group. Common in an absolute sense, barely different from the comparison group.

How long do Zepbound headaches last?

No trial reports a duration, so any specific figure you see is clinical impression rather than published data. What the label does describe, for the gastrointestinal reactions rather than for headache, is that most occurred during dose escalation and decreased over time. Use the timing test above on your own pattern instead of a general number.

Do other GLP-1 medications cause headaches?

The labels differ. Wegovy lists headache at 14% against 10% on placebo, clearing the same threshold Zepbound's did not. That is not a direct comparison between the drugs, because the trials were separate and every label warns that rates across different trials cannot be compared directly, but the difference in what each label reports is real.

Does drinking more water help?

If dehydration is the route in your case, it addresses the cause rather than masking it, and the label's own warning about gastrointestinal reactions leading to volume depletion supports taking intake seriously. It will not help a headache that has nothing to do with intake, which is exactly what the timing test is for.

Should I take a painkiller for it?

Ask your pharmacist or prescriber, who knows what else you take and your kidney status, which matters here given the label's volume depletion warning. This page does not recommend medicines or doses.

Do headaches mean the dose is too high?

The evidence does not support reading it that way. The pooled figures rise across doses but with heavily overlapping confidence intervals and a P value of .429, which does not establish a dose relationship. If your headaches do track your dose increases, that is a useful observation to bring to your prescriber, and it is theirs to act on.

Why does my headache come two days after the injection?

No published trial data addresses within-week timing, so anyone giving you a confident mechanism for day two specifically is going beyond the evidence. The pattern is still worth recording, because a consistent one is something a prescriber can work with and a vague recollection is not.

Related reading

• Zepbound reviews: patient ratings, physician ratings and trial results set side by side.
• Zepbound injection site reactions: the rates by dose, and the line between a local reaction and hypersensitivity.
• Zepbound KwikPen needles: what fits, how many each pen uses, and the 30 day clock.
• Semaglutide side effects: the same questions for Ozempic and Wegovy.
• Mounjaro vs Ozempic vs Wegovy: how the medications differ.

If you want the record the timing test needs without building it yourself, Jabby keeps doses and symptoms on one timeline so a pattern is something you can see rather than something you have to recall. It is free on the App Store.

Sources

• Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023 Nov;29(11):2909-2918. PMID 37840095. DOI 10.1038/s41591-023-02597-w. ClinicalTrials.gov NCT04657016. Table 3, adverse events in at least 5% of either group; headache 27 of 287 (9.4%) against 22 of 292 (7.5%).
• Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, SPL version 40, published 2 September 2026. Read 29 September 2026. Table 1 and its inclusion criteria, section 5.3 acute kidney injury, section 6.1 gastrointestinal reactions and hypoglycemia, and the Medication Guide list of low blood sugar symptoms.
• Novo Nordisk. WEGOVY (semaglutide) injection, prescribing information. DailyMed, published 30 June 2026. Read 29 September 2026. Table 3, headache 14% against 10% on placebo, N=2,116 and N=1,261.
• Mishra R, Raj R, Elshimy G, et al. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023 Feb 9;7(4):bvad016. PMID 36789109. DOI 10.1210/jendso/bvad016. Ten trials, 6,836 participants; headache incidence 4.00%, 5.16% and 10.71% at 5, 10 and 15 mg, P = .429.